Your browser doesn't support javascript.
loading
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Moreau, Philippe; Kumar, Shaji K; San Miguel, Jesús; Davies, Faith; Zamagni, Elena; Bahlis, Nizar; Ludwig, Heinz; Mikhael, Joseph; Terpos, Evangelos; Schjesvold, Fredrik; Martin, Thomas; Yong, Kwee; Durie, Brian G M; Facon, Thierry; Jurczyszyn, Artur; Sidana, Surbhi; Raje, Noopur; van de Donk, Niels; Lonial, Sagar; Cavo, Michele; Kristinsson, Sigurdur Y; Lentzsch, Suzanne; Hajek, Roman; Anderson, Kenneth C; João, Cristina; Einsele, Hermann; Sonneveld, Pieter; Engelhardt, Monika; Fonseca, Rafael; Vangsted, Annette; Weisel, Katja; Baz, Rachid; Hungria, Vania; Berdeja, Jesus G; Leal da Costa, Fernando; Maiolino, Angelo; Waage, Anders; Vesole, David H; Ocio, Enrique M; Quach, Hang; Driessen, Christoph; Bladé, Joan; Leleu, Xavier; Riva, Eloisa; Bergsagel, Peter Leif; Hou, Jian; Chng, Wee Joo; Mellqvist, Ulf-Henrik; Dytfeld, Dominik; Harousseau, Jean-Luc.
Afiliación
  • Moreau P; Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France. Electronic address: philippe.moreau@chu-nantes.fr.
  • Kumar SK; Department of Hematology, Mayo Clinic, Rochester, MN, USA.
  • San Miguel J; Applied Medical Research, Clínica Universidad de Navarra, University of Navarra, and Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
  • Davies F; Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
  • Zamagni E; Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University School of Medicine, S Orsola Malpighi Hospital, Bologna, Italy.
  • Bahlis N; University of Calgary, Calgary, AB, Canada.
  • Ludwig H; First Department of Medicine Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Ottakring Clinic, Vienna, Austria.
  • Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.
  • Terpos E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
  • Martin T; University of California San Francisco Medical Center, San Francisco, CA, USA.
  • Yong K; Department of Haematology, Cancer Institute, University College London, London, UK.
  • Durie BGM; Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Facon T; Blood Disease Department, University Hospital of Lille, University of Lille, Lille, France.
  • Jurczyszyn A; Department of Hematology, Jagiellonian University Medical College, Krakow, Poland.
  • Sidana S; Department of Hematology, Stanford University, Stanford, CA, USA.
  • Raje N; Massachusetts General Hospital, Boston, MA, USA.
  • van de Donk N; Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands.
  • Lonial S; Emory University Medical School, Emory University, Atlanta, GA, USA.
  • Cavo M; Seràgnoli Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University School of Medicine, S Orsola Malpighi Hospital, Bologna, Italy.
  • Kristinsson SY; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Lentzsch S; Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
  • Hajek R; Department of Hematooncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Anderson KC; Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • João C; Clinical Centre Champalimaud, Lisbon, Portugal.
  • Einsele H; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
  • Sonneveld P; Erasmus Medical Center, Rotterdam, Netherlands.
  • Engelhardt M; Department of Haematology, Oncology, and Stem-Cell Transplantation, Interdisciplinary Cancer Center, University of Freiburg, Freiburg, Germany.
  • Fonseca R; Mayo Clinic, Scottsdale, AZ, USA.
  • Vangsted A; Rigshospitalet, Copenhagen University, Copenhagen, Denmark.
  • Weisel K; University Medical Center Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany.
  • Baz R; Moffitt Cancer Center, Tampa, FL, USA.
  • Hungria V; Department of Hematology, São Germano Clinic, São Paulo, Brazil.
  • Berdeja JG; Sarah Cannon Research Institute, Nashville, TN, USA.
  • Leal da Costa F; Division of Hematology and Oncology, School of Medicine, and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Maiolino A; Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
  • Waage A; Department of Hematology, St Olavs Hospital, Trondheim, Norway.
  • Vesole DH; Hackensack University Medical Center, New Jersey Medical School, Rutgers University, Hackensack, NJ, USA.
  • Ocio EM; University Hospital Marqués de Valdecilla, University of Cantabria, Santander, Spain.
  • Quach H; Department of Haematology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.
  • Driessen C; Kantosspital St Gallen, St Gallen, Switzerland.
  • Bladé J; Hospital Clinic of Barcelona, Barcelona, Spain.
  • Leleu X; Service d'Hématologie et Thérapie Cellulaire, Hôpital La Milétrie, and Centre d'investigation Clinique INSERM 1402, Poitiers University Hospital, Poitiers, France.
  • Riva E; Clinical Hospital Dr Manuel Quintela, University of the Republic, Montevideo, Uruguay; British Hospital, Montevideo, Uruguay.
  • Bergsagel PL; Mayo Clinic, Scottsdale, AZ, USA.
  • Hou J; Shanghai Chang Zheng Hospital, Shanghai, China.
  • Chng WJ; Cancer Science Institute of Singapore, and Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Mellqvist UH; Department of Hematology, South Elfsborg Hospital, Borås, Sweden.
  • Dytfeld D; Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
  • Harousseau JL; Western Cancer Institute, Nantes University Hospital, Saint-Herblain, France.
Lancet Oncol ; 22(3): e105-e118, 2021 03.
Article en En | MEDLINE | ID: mdl-33662288
ABSTRACT
This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Terapia Recuperativa / Guías de Práctica Clínica como Asunto / Resistencia a Antineoplásicos / Mieloma Múltiple / Recurrencia Local de Neoplasia / Antineoplásicos Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Terapia Recuperativa / Guías de Práctica Clínica como Asunto / Resistencia a Antineoplásicos / Mieloma Múltiple / Recurrencia Local de Neoplasia / Antineoplásicos Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article